Floatz logo

TAURURSODIOL

Amyloidosis; Heart (Manifestation)

Brigham and Women's HospitalSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Amyloidosis; Heart (Manifestation) cohort.

Asset / SponsorPhaseRating
Acoramidis
Bayer
Phase 4BBB
DEXAMETHASONE
Ascentage Pharma Group Inc.
Phase 3BB
Empagliflozin
Columbia University
Phase 4BB
fx-1006a
Pfizer
Phase 4BB
cc-5013
Ascentage Pharma Group Inc.
Phase 3BB

View all 38 →

Same molecule, other indications

TAURURSODIOL is also rated in:

amyotrophic lateral sclerosisDormant
BBB
Indicative ·
74 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
64 / 100
View asset →
wild type ATTR amyloidosisDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →